Physician profile
Marcelo Blaya
NPI 1689885022
$1,420.40
in general payments reported to CMS, 2019-2025
15 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.68 · 2020: $118 · 2021: $56.93 · 2022: $72.95 · 2023: $214 · 2024: $84.99 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.64 |
| Education | $109.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $223.72 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $222.32 | 2022-2025 | Enhertu |
| Lilly USA, LLC | $212.28 | 2020-2025 | Verzenio |
| Pfizer INC. | $200.49 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $118.62 | 2023-2025 | Keytruda, Lynparza |
| Amgen INC. | $65.08 | 2021-2025 | Vectibix |
| Gilead Sciences, INC. | $57.09 | 2021-2025 | Trodelvy |
| Ge Healthcare | $54.44 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $53.89 | 2025 | Enhertu |
| Janssen Biotech, INC. | $52.53 | 2019-2022 | |
| Puma Biotechnology, INC. | $44.17 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $34.71 | 2025 | |
| Beone Medicines USA, INC. | $29.99 | 2025 | Tevimbra |
| Myriad Genetic Laboratories, INC. | $25.82 | 2023 | Myrisk |
| Aimmune Therapeutics, INC. | $25.25 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcelo Blaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.